Sponsored Content
Tyrolean Biotech Company Cyprumed Closes 493 Million Dollar Deal with American MSD
The Innsbruck-based biotechnology company Cyprumed GmbH is making international headlines with a multi-million dollar license deal: Together with the U.S. pharmaceutical group MSD (Merck & Co., Inc.), the company has signed an agreement worth up to 493 million US dollars. The aim is to develop innovative tablet formulations for peptide drugs - a potential game changer in modern drug therapies.
Merck & Co., Inc. is a US pharmaceutical company based in Rahway, New Jersey, which was originally part of the German Merck Group and operates outside the USA and Canada under the name Merck Sharp & Dohme (MSD). / Picture: © Wikimedia Commons / Coolcaesar / CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/deed.en)
As both companies announced on Tuesday, the agreement includes a non-exclusive license to Cyprumed's technology platform for the oral administration of peptides. This should make it possible in the future to take previously injectable peptide drugs—for example, for the treatment of diabetes, obesity, or cancer—in the form of tablets.
“Our platform for oral peptide…
or Log In
Fast News Search